Glancy Prongay Wolke & Rotter LLP reminds investors that the deadline to file a lead plaintiff motion in the class action against ADMA Biologics, Inc. is August 10, 2026. The lawsuit covers investors who purchased ADMA securities between August 9, 2024 and March 25, 2026. The complaint alleges the company made false and misleading statements and failed to disclose that it engaged in an undisclosed related party transaction and used channel stuffing to inflate revenue. On March 24, 2026, Culper Research published a report claiming ADMA induced a distributor to stock excess ASCENIV by offering rebates and extended payment terms, causing the stock to fall 29.1% over two days to close at $9.63 per share on March 25, 2026.
ADMA Biologics IncSecurities fraud lawsuit alleging false statements and channel stuffing to inflate revenue.